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When Kai-Uwe Eckardt, an internationally renowned nephrol-
ogist, was asked at the 2nd International Meeting on Renal MRI
in Berlin what he expected from magnetic resonance imaging
(MRI) of the kidneys he answered without hesitation, ‘A lot!’
This short answer expresses the unmet need for improved im-
aging methods that many in the nephrology community sense.
But how far away is a wider use of renal MRI in clinical
practice?
MRI has come a long way since the 1970s, when the first
cross-sectional MRI images of two test tubes were generated
[1]. This was closely followed by the development of fast-scan
techniques that were an essential step in the adoption of MRI as
a clinical diagnostic tool [2], and then the first MRI scans in
man [3, 4]. Modern MRI can generate exquisitely detailed ana-
tomical images, but crucially now also encompasses functional
MRI. With respect to the kidney, these techniques provide the
opportunity to assess total renal volume, the volume of different
compartments (i.e. cortex and medulla), function, perfusion,
oxygenation, oedema and potentially also the degree of fibrosis
or inflammation. Many of these measures can be combined
within a single scan session (multiparametric MRI), and do not
need the administration of contrast agents, a major advantage
in renal patients. As such, MRI has few contra-indications, and
estimates suggest that>95% of chronic kidney disease (CKD)
patients could potentially undergo renal MRI. Figure 1 provides
a (non-exhaustive) overview of some of the currently available
techniques.
To quote Pottumarthi Prasad, functional MRI is motivated
by the following: (i) to better understand physiology and patho-
physiology; (ii) to provide more comprehensive characteriza-
tion of pathological lesions; (iii) to provide a more sensitive
or earlier index of disease progression; and (iv) to target
therapy to the individual (personalized medicine) along with
measurement of response [5]. In terms of kidney diseases, these
principles are highly relevant. The prevalence of CKD is consid-
erable and still rising; ultrasound is the only imaging modality
used in the majority of patients and provides only limited infor-
mation. In large CKD cohorts, only 25% of all CKD patients
under the care of nephrologists have undergone a biopsy, and
in a similar proportion the cause of CKD is designated as un-
known [6, 7]. New imaging methods to identify, characterize
and track kidney damage at an early stage are urgently needed;
such methods will also have the potential to contribute to the
development and successful application of new therapies. To
this end, newer renal MRI techniques offer great potential to
generate diagnostic, prognostic, predictive, monitoring and
safety biomarkers.
However, we have to acknowledge that there are challenges
and knowledge gaps that must be addressed before renal MRI
methods can be more widely adopted in clinical research and
ultimately be transferred to clinical practice. Some of these chal-
lenges are technical. Unwanted variation in acquisition, analysis
and post-processing approaches need to be reduced, and
improvements made in standardizing patient preparation. This
is reflected in many MRI techniques being restricted to the re-
search settings in which they were developed. Knowledge gaps
include the biological basis of different MRI biomarkers, and
how the application of these biomarkers will improve patient
care. In addition, the limited availability of MRI scanners and
the expense of scanning time eventually need to be offset by a
positive health economic impact. All of these factors hinder the
set-up of multi-centre trials, limit commercial exploitation and
delay translation into clinical practice.
To address these important issues, a multinational group,
funded by a European Union COST (European Cooperation in
Science and Technology) Action, has recently been formed
VC The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial








Nephrol Dial Transplant (2018) 33: ii1–ii3
doi: 10.1093/ndt/gfy181
called ‘PARENCHIMA’: Magnetic Resonance Imaging
Biomarkers for Chronic Kidney Disease (www.renalmri.org).
PARENCHIMA aims to eliminate the barriers to the broader
study, commercial exploitation and clinical use of functional re-
nal MRI biomarkers, initially focusing on CKD but with the po-
tential to generalize to a number of other areas, including renal
transplantation and acute kidney injury, cardiorenal syndrome
and renovascular disease. This multidisciplinary group brings
together a large network of leading nephrologists, radiologists,
MRI physicists, medical imaging experts, histopathologists,
physiologists and clinical researchers with internationally rec-
ognized expertise in the field of renal MRI and CKD and links
to a number of other national and international initiatives (e.g.
UK renal imaging network, www.kidneyresearchuk.org/re
search/uk-renal-imaging-network; Biomarker Enterprise to
Attack Diabetic Kidney Disease—BEAT-DKD, www.beat-dkd.
eu; the National Unified Renal Translational Research
Enterprise—NURTuRE, www.nurturebiobank.org; German
Chronic Kidney Disease—GCKD Study, https://www.gckd.org;
Chronic Kidney Disease–Epidemiology and Information
Network Nephrology—CKD-REIN, ckdrein.inserm.fr).
This special supplement of Nephrology Dialysis
Transplantation, written collaboratively by international
experts from PARENCHIMA, aims to support future activities
of PARENCHIMA and other renal MRI research groups. The
key clinical questions that renal MRI must address to become
more widely used in patients with kidney disease, as well as a se-
ries of practical recommendations to accelerate renal MRI clini-
cal research, are presented in a position paper [8]. This is then
followed by four in-depth reviews of the most commonly used
and promising renal functional MRI techniques: diffusion-
weighted MRI (DWI) [9], blood oxygen level dependent
(BOLD) MRI [10], arterial spin labelling (ASL) [11] and T1/T2
mapping of the kidney [12]. Each review paper presents the cur-
rent status of scientific knowledge in each MRI modality, pro-
vides an overview of all studies performed so far in the human
kidney (excluding those pertaining to kidney cancer), presents
published ranges in healthy and kidney disease populations and
discusses current and future clinical application. These papers
also highlight current limitations, gaps in knowledge and unmet
needs of each individual MRI modality. In combination, these
articles provide a comprehensive description of the current sta-
tus quo, with the aim of aligning and accelerating technical
developments, standardization and clinical research. Thus, this
supplement should become an essential document for all
researchers and clinicians interested in MRI and renal diseases.
We firmly believe that the potential of renal MRI biomarkers is
immense; collaborative efforts such as PARENCHIMA are
needed to move the field forwards and will allow us to prove
that MRI really does have ‘a lot’ to offer.
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FIGURE 1: Overview of the clinical questions nephrologists may answer, now or in the near future, with functional MRI. The techniques
shown in bold are discussed in this supplement. DCE, dynamic contrast enhanced; ADPKD, autosomal dominant polycystic kidney disease;
DTI, diffusion tensor imaging.
ii2 A. Caroli et al.
FUNDING
M.P. is supported by a grant from the Swiss National Science
Foundation (FN 320030-169191).
CONFLICT OF INTEREST STATEMENT
None declared.
REFERENCES
1. Lauterbur PC. Image formation by induced local interactions: examples
employing nuclear magnetic resonance.Nature 1973; 242: 190–191
2. Mansﬁeld P, Grannell PK. ‘Diffraction’ and microscopy in solids and liquids
by NMR. Phys Rev B Condens Matter 1975; 12: 3618–3634
3. Mansﬁeld P, Maudsley AA. Medical imaging by NMR. Br J Radiol 1977; 50:
188–194
4. Damadian R, Goldsmith M, Minkoff L. NMR in cancer: XVI. FONAR im-
age of the live human body. Physiol Chem Phys 1977; 9: 97–100
5. Prasad PV. Functional MRI of the kidney: tools for translational studies of
pathophysiology of renal disease. Am J Physiol Ren Physiol 2006; 290:
F958–F974
6. Titze S, Schmid M, Ko¨ttgen A et al. Disease burden and risk proﬁle in re-
ferred patients with moderate chronic kidney disease: composition of the
German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant
2015; 30: 441–451
7. Stengel B, Metzger M, Combe C et al. Risk proﬁle, quality of life and care of
patients with moderate and advanced CKD: The French CKD-REIN
Cohort Study. Nephrol Dial Transplant 2018. doi: 10.1093/ndt/gfy058
8. Selby NM, Blankestijn PJ, Boor P et al. Magnetic resonance imaging
biomarkers for chronic kidney disease: a position paper from the
European Cooperation in Science and Technology Action PARENCHIMA.
Nephrol Dial Transplant 2018; 33 (Suppl 2): ii4–ii14
9. Caroli A, Schneider M, Friedli I et al. Diffusion-weighted magnetic reso-
nance imaging to assess diffuse renal pathology: a systematic review and
statement paper.Nephrol Dial Transplant 2018; 33 (Suppl 2): ii29–ii40
10. Pruijm M, Mendichovszky IA, Liss P et al. Renal blood oxygenation
level-dependent magnetic resonance imaging to measure renal tissue oxy-
genation: a statement paper and systematic review. Nephrol Dial Transplant
2018; 33 (Suppl 2): ii22–ii28
11. Odudu A, Nery F, Harteveld AA et al. Arterial spin labelling MRI to mea-
sure renal perfusion: a systematic review and statement paper. Nephrol Dial
Transplant 2018; 33 (Suppl 2): ii15–ii21
12. Wolf M, de Boer A, Sharma K et al. Magnetic resonance imaging T1- and
T2-mapping to assess renal structure and function: a systematic review and
statement paper.Nephrol Dial Transplant 2018; 33 (Suppl 2): ii41–ii50
Received: 14.5.2018; Editorial decision: 15.5.2018
Editorial ii3
